Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment
| Autor: | Mei Hong Xiu, Xiaoe Lang, Dachun Chen, Xiang Yang Zhang, Bo Cao, Huixia Zhou, Dongmei Wang, Li Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Pharmacology
First episode medicine.medical_specialty Risperidone business.industry Hippocampal formation medicine.disease Hippocampus Magnetic Resonance Imaging Drug-naïve Schizophrenia Internal medicine medicine Humans Pharmacology (medical) Original Article Neurology (clinical) Association (psychology) business medicine.drug Antipsychotic Agents |
| Zdroj: | Neurotherapeutics |
| Popis: | Small hippocampal size, especially in CA1 may be implicated in the pathogenesis and psychopathology of schizophrenia (SCZ). However, does the volume of hippocampal subfields like CA1 in SCZ patients affect response to antipsychotic treatment? In this study, we used risperidone to treat first-episode and drug naïve (FEDN) SCZ patients for 12 weeks, and then explored the relationship between differences in baseline hippocampal subfield volumes, as well as any changes in the volumes of these hippocampal structures during treatment, and improvement in their psychopathological symptoms. By adopting a state-of the-art automated algorithm, the hippocampal subfields were segmented in 43 FEND SCZ inpatients at baseline and in 26 of them after 12 weeks of risperidone monotherapy, as well as in 30 matched healthy controls. We adopted the Positive and Negative Syndrome Scale (PANSS) to assess psychopathological symptoms in 43 SCZ patients at baseline and in 40 of them at post-treatment. Our results showed that before treatment, schizophrenia patients had no significant differences in total or subfield hippocampal volumes compared with healthy volunteers (all p>0.05). However, at baseline smaller volumes of the left CA1, right molecular layer of the dentate, left hippocampal tail and left pre-subiculum were significantly correlated with worse PANSS negative symptom scores, accounting for 41% of its variance. We also found a significant correlation between a larger left CA1 at baseline and a worse PANSS total score and general psychopathology sub-score at post-treatment (both p50% improvement in PANSS total score, than in non-responders (p50% improvement in PANSS total score after 12 weeks of risperidone treatment. Thus, smaller left CA1 volume may be a predicator for improvement in psychotic symptoms of FEDN SCZ patients, but hippocampal volumes overall did not differ in size from normal controls and did not change during treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|